Mannkind Corp
MNKD - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.13B
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $1.13 Billion |
|---|---|
| Enterprise Value | $1.41 Billion |
| Earnings per Share | $0.02 |
| Beta | 1.08 |
| Outstanding Shares | 309,191,000 |
Return
| Return on Equity | 64.90% |
|---|---|
| Return on Assets | -5.96% |
| Return on Invested Capital | 2.71% |
Valuation & Multiples
| P/E Ratio | -25.09 |
|---|---|
| PEG | 0.85 |
| Price to Sales | 3.65 |
| Price to Book Ratio | -3.65 |
| Enterprise Value to Revenue | 3.59 |
| Enterprise Value to EBIT | 88.45 |
| Enterprise Value to Net Income | -33 |
| Total Debt to Enterprise | 0.24 |
| Debt to Equity | -5.09 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$-0.01
Consensus analyst estimateRevenue Estimate
$108.08 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$-0.06
Consensus analyst estimateRevenue Estimate
$107.74 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 138.19% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.96%▼ 57.85% |
|---|---|
| Total Invested | $23.34M▼ 97.04% |
| Investors Holding | 60▼ 208.00% |
About Mannkind Corp
233 employees
CEO: Michael Castagna
MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder,...